Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. Pusztai · SciRah

Researcher profile · Semantic Scholar

L. Pusztai

Share profile

L. Pusztai — researcher profile on SciRah

h-index: 110
Works: 867
Citations: 59K

Most-cited papers

Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.
Aileen I. Fernandez, Matthew Liu, A. Bellizzi, J. Brock +19 more
2022JAMA Oncology314 citations Open access
Semantic Scholar
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
F. André, Nofisat Ismaila, K. Allison, W. Barlow +12 more
2022Journal of Clinical Oncology311 citations Open access
Semantic Scholar
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies
D. Wolf, C. Yau, J. Wulfkuhle, L. Brown-Swigart +29 more
2022Cancer Cell295 citations Open access
Semantic Scholar
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
J. Litton, M. Regan, L. Pusztai, H. Rugo +23 more
2023Journal of Clinical Oncology95 citations Open access
Semantic Scholar
Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors
P. Kasi, G. Fehringer, H. Taniguchi, N. Starling +18 more
2022JCO Precision Oncology92 citations Open access
Semantic Scholar
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and/or BRCA mutation-associated breast cancer (S1416): a randomised, phase 2 trial
E. Rodler, Priyanka Sharma, W. Barlow, J. Gralow +17 more
2023The Lancet Oncology67 citations Open access
Semantic Scholar
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer
Iván Pérez-Núñez, Catalina Rozalén, José Ángel Palomeque, Irene Sangrador +27 more
2022Nature Cancer63 citations Open access
Semantic Scholar
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
C. Liedtke, C. Mazouni, K. Hess, F. André +9 more
2023Journal of Clinical Oncology62 citations
Semantic Scholar
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
D. Page, G. Broeckx, C. Jahangir, Sara Verbandt +130 more
2023Journal of Pathology57 citations Open access
Semantic Scholar
Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
J. Thagaard, G. Broeckx, D. Page, C. Jahangir +138 more
2023Journal of Pathology54 citations Open access
Semantic Scholar
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification.
D. Trapani, M. Franzoi, H. Burstein, L. Carey +13 more
2022Annals of Oncology48 citations Open access
Semantic Scholar
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.
L. Pusztai, C. Denkert, J. O'Shaughnessy, J. Cortés +15 more
2022Journal of Clinical Oncology40 citations
Semantic Scholar
Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer
K. Blenman, M. Marczyk, T. Karn, T. Qing +16 more
2022Clinical Cancer Research34 citations Open access
Semantic Scholar
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
T. Qing, T. Karn, M. Rozenblit, J. Foldi +7 more
2022npj Breast Cancer32 citations Open access
Semantic Scholar
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
M. Lambertini, M. Ceppi, R. Anderson, D. Cameron +24 more
2023The Journal of the National Comprehensive Cancer Network31 citations Open access
Semantic Scholar
In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer
Lin-Geng Lu, Wen-Xue Ma, Caroline H. Johnson, Sajid Khan +2 more
2023Vaccine24 citations Open access
Semantic Scholar
More than bad luck: Cancer and aging are linked to replication-driven changes to the epigenome
Christopher Minteer, Kyra L. Thrush, John T. González, Peter Niimi +12 more
2023Science Advances24 citations Open access
Semantic Scholar
Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial.
R. Jagsi, W. Barlow, W. Woodward, E. Connolly +10 more
2023JAMA Oncology22 citations Open access
Semantic Scholar
Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
M. Marczyk, A. Mrukwa, C. Yau, D. Wolf +27 more
2022Annals of Oncology20 citations Open access
Semantic Scholar
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
G. Curigliano, R. Dent, A. Llombart-Cussac, M. Pegram +3 more
2023npj Breast Cancer19 citations Open access
Semantic Scholar
Clinical outcomes and immune markers by race in a Phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBC
J. Foldi, A. Kahn, A. Silber, T. Qing +11 more
2022Clinical Cancer Research19 citations
Semantic Scholar
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
Mattia Rediti, A. Fernández-Martínez, D. Venet, F. Rothé +18 more
2023Nature Communications18 citations Open access
Semantic Scholar
Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
N. Danziger, E. Sokol, R. Graf, M. Hiemenz +6 more
2023The Oncologist18 citations Open access
Semantic Scholar
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Rachel Jaber Chehayeb, Annette Hood, Xiao-Liang Wang, R. Miksad +6 more
2022JAMA Network Open18 citations Open access
Semantic Scholar
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
L. Licata, G. Viale, M. Giuliano, G. Curigliano +18 more
2023npj Breast Cancer17 citations Open access
Semantic Scholar
Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer
A. Nanou, Jieling Miao, F. Coumans, E. Dolce +11 more
2023JCO Precision Oncology16 citations Open access
Semantic Scholar
Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms
Joanna Żyła, Anna Papiez, Jun Zhao, Rihao Qu +6 more
2023Computational and Structural Biotechnology Journal13 citations Open access
Semantic Scholar
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
K. Fanucci, Ya-Lai Bai, V. Pelekanou, Z. Nahleh +13 more
2023npj Breast Cancer12 citations Open access
Semantic Scholar
Comprehensive Analysis of Metabolic Isozyme Targets in Cancer
M. Marczyk, V. Gunasekharan, D. Casadevall, T. Qing +13 more
2022Cancer Research12 citations Open access
Semantic Scholar
De Novo Oligometastatic Breast Cancer.
L. Pusztai, M. Rozenblit, P. Dubsky, T. Bachelot +7 more
2023Journal of Clinical Oncology11 citations
Semantic Scholar
Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007)
Y. Abdou, W. Barlow, J. Gralow, F. Meric-Bernstam +20 more
2023Cancer Research11 citations
Semantic Scholar
MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.
P. Beitsch, J. Pellicane, L. Pusztai, P. Baron +13 more
2023Journal of Clinical Oncology10 citations Open access
Semantic Scholar
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)
M. Bergqvist, Adrian Nordmark, Amy Williams, C. Paoletti +12 more
2023Biomarkers10 citations Open access
Semantic Scholar
Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer
A. Kahn, R. Golestani, M. Harigopal, L. Pusztai
2023Breast Cancer Research and Treatment9 citations
Semantic Scholar
Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing
M. Marczyk, C. Fu, R. Lau, L. Du +6 more
2023Cancer Cytopathology9 citations
Semantic Scholar
Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).
D. Wolf, C. Yau, M. Campbell, A. Glas +15 more
2023Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
C. Speers, W. Symmans, W. Barlow, Alexander J. Trevarton +12 more
2023Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses
P. Schmid, J. Cortés, R. Dent, L. Pusztai +26 more
2022Cancer Research9 citations
Semantic Scholar
Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
L. Huppert, H. Rugo, L. Pusztai, R. Mukhtar +8 more
2022Journal of Clinical Oncology9 citations
Semantic Scholar
Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest
Leah S. Kim, Magdalena M. Coman, L. Pusztai, T. Park
2023Annals of Surgical Oncology8 citations
Semantic Scholar
PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer
M. Rozenblit, K. Blenman, M. Harigopal, Emily S. Reisenbichler +10 more
2022Breast Cancer Research and Treatment8 citations
Semantic Scholar
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors
C. Dieli-Conwright, Maura Harrigan, B. Cartmel, A. Chagpar +7 more
2022npj Breast Cancer8 citations Open access
Semantic Scholar
Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study
H. McArthur, J. Cortés, R. Dent, J. O'Shaughnessy +15 more
2023Cancer Research6 citations
Semantic Scholar
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
J. Foldi, Anastasia Tsagianni, M. Salganik, C. Schnabel +4 more
2023BMC Cancer6 citations Open access
Semantic Scholar
Abstract OT1-12-04: A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)
N. Harbeck, J. Boileau, S. Modi, C. Kelly +6 more
2022Cancer Research6 citations
Semantic Scholar
Systemic Staging of Locally Advanced Breast Cancer: How Hard to Look?
L. Pusztai
2023Journal of Clinical Oncology5 citations
Semantic Scholar
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
Hao-Kuen Lin, Thuy Can, Adriana M. Kahn, Cynthia A. Flannery +6 more
2023The Oncologist4 citations Open access
Semantic Scholar
Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
Beverly Kyalwazi, C. Yau, O. Olopade, J. Chien +32 more
2022Cancer Research4 citations
Semantic Scholar
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.
M. Cecchini, E. Sokol, N. Vasan, D. Pavlick +8 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar
Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
J. Foldi, A. Silber, Emily S. Reisenbichler, Kamaljeet Singh +17 more
2022npj Breast Cancer4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Blenman×9
Invite
K. Blenman — researcher profile on SciRah
D. Rimm×8
Invite
D. Rimm — researcher profile on SciRah
W. Barlow×8
Invite
W. Barlow — researcher profile on SciRah
G. Hortobagyi×8
Invite
G. Hortobagyi — researcher profile on SciRah

Priyanka Sharma

×7

Invite

Priyanka Sharma — researcher profile on SciRah

Invite

M. Marczyk — researcher profile on SciRah

Invite

J. Foldi — researcher profile on SciRah

Invite

W. Symmans — researcher profile on SciRah

Invite

T. Qing — researcher profile on SciRah

M. Rozenblit×6

Invite

M. Rozenblit — researcher profile on SciRah

Emily S. Reisenbichler×5

Invite

Emily S. Reisenbichler — researcher profile on SciRah

Invite

K. Kalinsky — researcher profile on SciRah